3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
2
Phase 2
1
Status
Unknown
2
Completed
1
Sponsor Class
OTHER
2
INDUSTRY
1
Study Type
Interventional
3
Sponsor
Cancer Type
Other solid neoplasm
3
Conditions
Carcinoma, Non-Small-Cell Lung
149
Breast Neoplasms
87
Colorectal Neoplasms
64
Neoplasms
53
Pancreatic Neoplasms
52
Lung Neoplasms
49
Neoplasm Metastasis
45
Stomach Neoplasms
43
Ovarian Neoplasms
42
Rectal Neoplasms
41
Esophageal Squamous Cell Carcinoma
34
Esophageal Neoplasms
33
Squamous Cell Carcinoma of Head and Neck
30
Head and Neck Neoplasms
30
Leukemia, Myeloid, Acute
28
Recurrence
23
Triple Negative Breast Neoplasms
22
Precursor Cell Lymphoblastic Leukemia-Lymphoma
22
Small Cell Lung Carcinoma
20
Nasopharyngeal Carcinoma
20
Glioblastoma
20
Uterine Cervical Neoplasms
19
Fallopian Tube Neoplasms
19
Lymphoma, Non-Hodgkin
18
Lymphoma
18
Colonic Neoplasms
17
Prostatic Neoplasms
16
Leukemia
15
Carcinoma, Ovarian Epithelial
15
Melanoma
14
Interventions
pembrolizumab
14
Injections
13
Paclitaxel
10
Nivolumab
10
Docetaxel
9
Cisplatin
9
Capecitabine
8
Bevacizumab
8
toripalimab
7
senaparib
7
Cyclophosphamide
7
tislelizumab
6
atezolizumab
6
Irinotecan
6
Gemcitabine
5
Fluorouracil
5
fludarabine
4
apatinib
4
Oxaliplatin
4
Leucovorin
4
Ipilimumab
4
Fluorodeoxyglucose F18
4
spartalizumab
3
pertuzumab
3
olaparib
3
camrelizumab
3
Rifampin
3
Radiosurgery
3
Midazolam
3
Itraconazole
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Solid Tumor
×
Drug Therapy
×
Clear all
NCT05898451
2023-06-12
R-2
Refnot-Pharm Ltd
Phase 2
Completed
55 enrolled
NCT04214717
2023-03-28
DC-CIK
Yantai Yuhuangding Hospital
Phase NA
Unknown
60 enrolled
NCT04214730
2023-03-28
NK
Yantai Yuhuangding Hospital
Phase NA
Unknown
60 enrolled